

MYO3α, Active

Recombinant human protein expressed in Sf9 cells

Catalog # M65-11G

Lot # K1502-2

Product Description

Recombinant human MYO3α (1-434) was expressed by baculovirus in Sf9 insect cells using an N-terminal GST tag. The MYO3α gene accession number is [NM_017433](#).

Gene Aliases

myosin IIIA; DFNB30

Formulation

Recombinant protein stored in 50mM Tris-HCl, pH 7.5, 150mM NaCl, 10mM glutathione, 0.1mM EDTA, 0.25mM DTT, 0.1mM PMSF, 25% glycerol.

Storage and Stability

Store product at -70°C. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.


Scientific Background

MYO3α belongs to the myosin superfamily which are members of the large myosin superfamily and are categorized into conventional myosins (class II) and unconventional myosins (classes I and III through XV) based on their variable C-terminal cargo-binding domains. Class III myosins, such as MYO3α, have a kinase domain N-terminal to the conserved N-terminal motor domains and are expressed in photoreceptors (1). MYO3α plays an important role in hearing in humans and mutations in the MYO3α have been shown to cause nonsyndromic progressive hearing loss (2). MYO3α is highly expressed in retina and cochlea.

References


1. Dose, A. C.et.al: Cloning and chromosomal localization of a human class III myosin. *Genomics* 67: 333-342, 2000.
2. Walsh, V. L.et.al: A mouse model for human hearing loss DFNB30 due to loss of function of myosin IIIA. *Mammalian Genome* 22: 170-177, 2011.

Specific Activity



The specific activity of MYO3α was determined to be **4.5 nmol /min/mg** as per activity assay protocol.

Purity



The purity of MYO3α was determined to be **>80%** by densitometry. Approx. MW **76kDa**.

MYO3α, Active

Recombinant human protein expressed in Sf9 cells

Catalog #	M65-11G
Specific Activity	4.5 nmol/min/mg
Lot #	K1502-2
Purity	>80%
Concentration	0.1 µg/µl
Stability	1yr at -70°C from date of shipment
Storage & Shipping	Store product at -70°C. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles. Product shipped on dry ice.

Activity Assay Protocol

Reaction Components

Active Kinase (Catalog #: M65-11G)

Active MYO3 α (0.1 μ g/ μ l) diluted with Kinase Dilution Buffer III (Catalog #: K23-09) and assayed as outlined in sample activity plot. (Note: these are suggested working dilutions and it is recommended that the researcher perform a serial dilution of Active MYO3 α for optimal results).

Kinase Dilution Buffer III (Catalog #: K23-09)

Kinase Assay Buffer I (Catalog #: K01-09) diluted at a 1:4 ratio (5X dilution) with 50 ng/ μ l BSA solution.

Kinase Assay Buffer I (Catalog #: K01-09)

Buffer components: 25mM MOPS, pH 7.2, 12.5mM β -glycerol-phosphate, 25mM MgCl₂, 5mM EGTA, 2mM EDTA. Add 0.25mM DTT to Kinase Assay Buffer prior to use.

[³³P]-ATP Assay Cocktail

Prepare 250 μ M [³³P]-ATP Assay Cocktail in a designated radioactive working area by adding the following components: 150 μ l of 10mM ATP Stock Solution (Catalog #: A50-09), 100 μ l [³³P]-ATP (1mCi/100 μ l), 5.75ml of Kinase Assay Buffer I (Catalog #: K01-09). Store 1ml aliquots at -20°C.

10mM ATP Stock Solution (Catalog #: A50-09)

Prepare ATP stock solution by dissolving 55mg of ATP in 10ml of Kinase Assay Buffer I (Catalog #: K01-09). Store 200 μ l aliquots at -20°C.

Substrate (Catalog #: M42-51N)

Myelin basic protein (MBP) diluted in distilled H₂O to a final concentration of 1mg/ml.

Assay Protocol

- Step 1.** Thaw [³³P]-ATP Assay Cocktail in shielded container in a designated radioactive working area.
- Step 2.** Thaw the Active MYO3 α , Kinase Assay Buffer, Substrate and Kinase Dilution Buffer on ice.
- Step 3.** In a pre-cooled microfuge tube, add the following reaction components bringing the initial reaction volume up to 20 μ l:
 - Component 1.** 10 μ l of diluted Active MYO3 α (Catalog #M65-11G)
 - Component 2.** 5 μ l of 1mg/ml stock solution of substrate (Catalog #M42-51N)
 - Component 3.** 5 μ l distilled H₂O (4°C)
- Step 4.** Set up the blank control as outlined in step 3, excluding the addition of the substrate. Replace the substrate with an equal volume of distilled H₂O.
- Step 5.** Initiate the reaction by the addition of 5 μ l [³³P]-ATP Assay Cocktail bringing the final volume up to 25 μ l and incubate the mixture in a water bath at 30°C for 15 minutes.
- Step 6.** After the 15 minute incubation period, terminate the reaction by spotting 20 μ l of the reaction mixture onto individual pre-cut strips of phosphocellulose P81 paper.
- Step 7.** Air dry the pre-cut P81 strip and sequentially wash in a 1% phosphoric acid solution (dilute 10ml of phosphoric acid and MYO3Ae a 1L solution with distilled H₂O) with constant gentle stirring. It is recommended that the strips be washed a total of 3 intervals for approximately 10 minutes each.
- Step 8.** Count the radioactivity on the P81 paper in the presence of scintillation fluid in a scintillation counter.
- Step 9.** Determine the corrected cpm by removing the blank control value (see Step 4) for each sample and calculate the kinase specific activity as outlined below.

Calculation of [³³P]-ATP Specific Activity (SA) (cpm/pmol)

Specific activity (SA) = cpm for 5 μ l [³³P]-ATP / pmoles of ATP (in 5 μ l of a 250 μ M ATP stock solution, i.e., 1250 pmoles)

Kinase Specific Activity (SA) (pmol/min/ μ g or nmol/min/mg)

Corrected cpm from reaction / [(SA of ³³P-ATP in cpm/pmol)*(Reaction time in min)*(Enzyme amount in μ g or mg)]*[(Reaction Volume) / (Spot Volume)]

To place your order, please contact us by phone 1-(604)-232-4600, fax 1-604-232-4601 or by email: orders@signalchem.com
www.signalchem.com

FOR IN VITRO RESEARCH PURPOSES ONLY. NOT INTENDED FOR USE IN HUMAN OR ANIMALS.